Short term effect of Intravenous Intermittent Iron Infusion versus Bolus Iron Infusion on Iron parameters in Hemodialysis patients
Article Sidebar
Main Article Content
Abstract
Intravenous iron is used in combination with erythropoi esis-stimulating agents to treat the anemia of hemodialysis patients, however, there is variety in the dose and the frequency. So we compare bolus intravenous iron administration protocol vs an intermittent intravenous iron infusion protocol for 3 months in a single blinded design that was conducted on 30 patients randomized into 2 matching groups. Iron parameter, hemoglobin level, and CRP were monitored before and at the end of study. Patients with end stage renal disease on regular hemodialysis with iron deficiency anemia can be treated with intravenous iron administration either by the protocol of divided doses of IV iron through the sessions of hemodialysis or by giving the total dose of iron needed as a single large dose on only one session of hemodialysis, obtaining the same outcome in correction of iron parameters in treatment of iron deficiency anemia.
Article Details
Copyright (c) 2017 Sarhan II, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Collins AJ, Li S, St Peter W, Ebben J, Roberts T, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001; 12: 2465-2473. Ref.: https://goo.gl/pc8Ad7
Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010; 6: 699-710. Ref.: https://goo.gl/BnBSEf
Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 19: 2019-2032. Ref.: https://goo.gl/S8UVDm
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 355: 2085-2098. Ref.: https://goo.gl/CV2DWR
Robinson BM, Fuller DS, Bieber BA, Turenne MN, Pisoni RL. The DOPPS Practice Monitor for US dialysis care: Trends through April 2011. Am J Kidney Dis. 2012; 59: 309-312. Ref.: https://goo.gl/142wo9
Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients. Am J Med. 2012; 125: 906-914. Ref.: https://goo.gl/9WXsR4
Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, et al. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol. 2015; 26: 1238-1247. Ref.: https://goo.gl/LTNZrC
Wetmore JB, Peng Y, Monda KL, Kats AM, Kim DH, et al. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: A retrospective cohort analysis. Am J Nephrol. 2015; 41: 354-361. Ref.: https://goo.gl/s6RmSQ
Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18: 975-984. Ref.: https://goo.gl/E4TEKS
Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, et al. The comparative short-term effectiveness of iron dosing and formulations in U.S. hemodialysis patients. Am J Med. 2013; 126: 541. Ref.: https://goo.gl/yzkkeu
Thakuria M, Ofsthun NJ, Mullon C, Diaz-Buxo JA. Anemia management in patients receiving chronic hemodialysis. Semin Dial. 2011; 24: 597-602. Ref.: https://goo.gl/65Yj7u
Yong K, Kairaitis L. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort. Nephrology (Carlton). 2010; 15: 288-293. Ref.: https://goo.gl/gzARxH
Besarab A. Anemia and iron management. Semin Dial. 2011; 24: 498-503. Ref.: https://goo.gl/efEXmw
Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LR, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50: 1694-1699. Ref.: https://goo.gl/7JPnK9
Locatelli F, Aligama P, Barany P, Canaud B, Carrera F, et al. European Best Practice Guidelines Working Group. Revised European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 2004; 19: 1-47. Ref.: https://goo.gl/Q9aeBu
Fenwick S, Peebles G. Total dose infusion of intravenous iron in patients with chronic kidney disease receiving haemodialysis. Journal of Renal Care. 2011; 37: 47-51. Ref.: https://goo.gl/fUjn9R
Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007; 18: 975-984. Ref.: https://goo.gl/JwhQM9
Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008; 19: 372-379. Ref.: https://goo.gl/Z2upWz
Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004; 15: 1623-1632. Ref.: https://goo.gl/9Tc7zt
Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 3070-3080. Ref.: https://goo.gl/KxPzSd
Abhijit VK, Janet KF, Alan RE, Lily W, Wolfgang CW, et al. Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis Patients. PLOS ONE. 2013. Ref.: https://goo.gl/NsBWDH